drugset / Trial / NCT00943410

Trastuzumab and External Beam Radiation Therapy in Treating Women With Stage III or Stage IV Breast Cancer

NCT00943410 ↗

Non-randomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Radiation therapy uses high-energy x-rays to kill tumor cells. Trastuzumab may make tumor cells more sensitive to radiation therapy. Giving trastuzumab together with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying the side effects and how well giving trastuzumab together with external beam radiation therapy works in treating women with stage III or stage IV breast cancer.

Timeline

Start
2000-03
Primary completion
2006-01
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Trastuzumab Monoclonal antibody 2 mg/kg Intravenous

Indications